Abstract
We characterized a novel substitution conferring moderate resistance to telaprevir, a peptidomimetic inhibitor of hepatitis C virus protease. V36C conferred a 4.0-fold increase in the telaprevir 50% inhibitory concentration in an enzyme assay and a 9.5-fold increase in the replicon model. The replication capacity of a replicon harboring V36C was close to that of the wild-type protease. This case emphasizes the complexity of hepatitis C virus resistance to protease inhibitors. Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Cite
CITATION STYLE
Barbotte, L., Ahmed-Belkacem, A., Chevaliez, S., Soulier, A., Hézode, C., Wajcman, H., … Pawlotsky, J. M. (2010). Characterization of V36C, a novel amino acid substitution conferring Hepatitis C Virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease. Antimicrobial Agents and Chemotherapy, 54(6), 2681–2683. https://doi.org/10.1128/AAC.01796-09
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.